News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: China National Biotech Group Plans $1.6 Billion Hong Kong IPO


9/10/2012 10:23:27 AM

by Richard Daverman, PhD

September 9, 2012 -- China National Biotec announced that its upcoming Hong Kong IPO, which now awaits only CSRC approval, will raise as much as $1.6 billion; Triplex International Biosciences, a Xiamen diagnostics company, received a $50 million capital infusion from private-equity firm RRJ Capital; The thirteenth ChinaBio® Investor Forum selected Optomed Oy from Finland and ASLAN Pharmaceuticals from Singapore as the “Most Promising” of the 18 presenting companies; WuXi PharmaTech will use Open Monoclonal Technology's OmniRat to develop therapeutic antibody candidates; liquidators found that China Medical Technologies, a previously high flying diagnostics company, has no assets; and Dainippon Sumitomo Pharma submitted an application to the SFDA for approval of amrubicin HCI, a treatment for small cell cancer. More details….

Stock Symbols: (NYSE: WX) (NSDQ: CMEDY)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES